IQVIA Holdings IQV
Healthcare · Medical - Diagnostics & Research · Synthos Deep Dive · 2026-07-03
The Overview
IQVIA is the company drug-makers hire to run their clinical trials and tell them how their medicines are selling. It sits on one of the world's biggest health-data sets and pairs that with a giant contract-research business — think "the plumbing and the map for the pharma industry." Around 55% of its revenue comes from running trials (R&D Solutions), the rest from data, analytics, and sales services (Commercial Solutions).
Is the stock cheap or expensive? Fairly priced. You pay about 16 times next year's expected profit — reasonable for a high-quality, hard-to-replace business, but not a bargain. Our verdict is Buy — Tactical: worth owning in a smaller, "satellite" slice, but not as a bedrock holding, because the company carries a lot of debt and its sales wobble when biotech funding dries up.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit above average). The valuation is fair, but the company owes a lot of money and its stock swings with the market and with drug-industry budgets.
- Growth Quality 6/10 (solid). A good, profitable, sticky business — but it grows slowly (about 6% more sales a year), so it's steady rather than exciting.
- Exponential Potential 3/10 (low). It should keep growing modestly for years, but it is not going to double quickly — the growth is actually slowing, not speeding up.
The one big worry: most of IQVIA's revenue is trial work that clients can cancel on short notice, and that work shrinks when small drug companies can't raise money. If biotech funding stays tight, bookings and the stock both suffer.
Important honesty note: Synthos has no expert-analyst coverage on IQVIA in its knowledge base. This write-up is built entirely from the financial data and our own models — there is no panel of investors backing it, so treat the conviction as low.
Putting a number on it: our fair-value estimate is $227 against a current price of $261.75 — a premium price for a business we still like.
Our summary metrics
Reasonable 16× fwd P/E & low-teens EV/EBITDA, but 4.0× net-debt/EBITDA and beta 1.2 with biotech-funding cyclicality.
~6% fwd revenue CAGR but ~12% adj-EPS CAGR, 21% EBITDA margin, 22% ROE, sticky data moat — steady, not spectacular.
Decelerating top line, $34B cap vs a large but slow-growing CRO/analytics TAM — a compounder, not a multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Decelerating top line, $34B cap vs a large but slow-growing CRO/analytics TAM — a compounder, not a multibagger.
“Most COVID disruption is behind us; 2021 marks a return to growth trajectory with strong recovery across segments.”
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $222.4 (high $250 / low $185; 1 Strong Buy · 35 Buy · 7 Hold · 1 Sell) — context, not our anchor |
| Valuation | 25× trailing EPS · ~16× FY26E adj · ~15× FY27E adj · ~10× FY30E adj · EV/S 2.9× · EV/EBITDA 13.8× |
| Technicals | Recovering uptrend — $207, −15% off 52-wk high, above 50/200-DMA, RSI 73.6 (overbought), +27% 12-mo (SPY +21%) |
| Conviction | Low (breadth 0) — no expert voices in the Synthos KB; call rests on fundamentals + quant |
| Position sizing | Satellite/tactical, ~1.5–3% — a value-tilted quality name, not a core anchor |
What the company says Issuer statements only — no independent expert coverage yet for IQV
“Most COVID disruption is behind us; 2021 marks a return to growth trajectory with strong recovery across segments.”
These are the company’s own claims (management voices are always half-weighted in our scoring, never treated as independent validation) — shown because they’re the only claims on record for this name. Treat as company guidance, not third-party analysis.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $261.75, 18% above the 50-day average ($221), 30% above the 200-day average ($201) — an uptrend. 0% below the 52-week high of $262, 67% above the 52-week low of $157.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $261.75 is currently inside the band (band $224–$268).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 72.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.42, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = IQV · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
IQVIA Holdings (NYSE: IQV) is a ~$35B-market-cap global provider of clinical research services, commercial analytics, and healthcare data to the life-sciences industry. Formed from the 2016 merger of Quintiles (the world's largest contract research organization, or CRO) and IMS Health (the dominant pharma-data business), it employs ~93,000 people across 100+ countries and is run by long-tenured chairman/CEO Ari Bousbib. Fiscal year ends December 31.
As of January 1, 2026 the company re-segmented into two reporting units (down from three) — the deep-dive uses the historical three-segment FMP data for FY25 and the new two-segment view from management's Q1'26 release:
Revenue mix (FY2025, from filings — legacy three-segment view):
- Research & Development Solutions $8.90B (55%) — the CRO: clinical-trial management, monitoring, labs, virtual trials. Contracted backlog $34.2B (Q1'26).
- Technology & Analytics Solutions $6.63B (41%) — real-world data, cloud analytics, consulting, commercial outsourcing; the high-margin IMS-heritage data moat.
- Contract Sales & Medical Solutions $0.79B (5%) — field sales teams and medical-affairs support.
New two-segment view (Q1'26): Commercial Solutions $1.75B (+11.6% reported) and R&D Solutions $2.40B (+6.2% reported).
Revenue by geography (FY2025): Americas $7.75B (48%) · EMEA $5.19B (32%) · Asia-Pacific $3.38B (21%). Less US-concentrated than most healthcare names — a diversification strength but also an FX-translation exposure.
The strategic pitch is "Connected Intelligence" — layering Healthcare-grade AI and analytics on top of proprietary health data and the CRO franchise. Management flags AI-enabled offerings "gaining traction," but that is early and self-reported (§9).
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of IQVIA in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and there are zero traceable claim_ids. None of the investors, podcasts, or analysts distilled into the Synthos KB have made a signed, traceable call on this name.
This matters for how you read the verdict. Unlike a conviction-track name (where an independent expert panel backs the thesis), the IQV call is entirely fundamentals- and quant-driven: it rests on the reported financials, the analyst-consensus estimates (FMP), management's own guidance (half-weighted), and Synthos's own scoring and scenario models. We will not manufacture conviction we do not have — treat this as a data-and-model call with Low conviction, and size accordingly (§12).
The one non-KB, self-interested voice we do capture is management's own guidance, summarized and explicitly half-weighted in §9.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Valuation is fair (~16× FY26E adj EPS, EV/EBITDA 13.8×), so multiple risk is limited — but net-debt/EBITDA 4.0× (TTM; mgmt 3.62× on adj EBITDA), beta 1.2, a −27% peak-to-trough drawdown in the past year, and a cancellable, biotech-funding-sensitive order book push risk above average. |
| Growth Quality | 6 · Solid | ~6% forward revenue CAGR but ~12% adjusted-EPS CAGR (buybacks + margin), 21% EBITDA margin, 22% ROE, and a genuinely sticky data/CRO moat. Good, durable, unspectacular. |
| Exponential Potential | 3 · Low | Top line is decelerating (mid-single-digit organic), the TAM (CRO + pharma analytics) is large but slow-growing, and a $34.6B cap with 6% growth caps the upside. A compounder, not a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Biotech R&D funding recovers; R&DS bookings re-accelerate (book-to-bill >1.15×); AI-analytics offerings lift Commercial margins. FY27E adj EPS beats to ~$15; multiple re-rates to ~18×. | ~$270 (+30%) |
| Base (our anchor) | Estimates roughly hit — FY27E adj EPS ~$14.2; a steady high-single-digit-EPS compounder holds a ~16× multiple as leverage slowly de-risks. | ~$227 (+10%) |
| Bear | Biotech funding stays tight, R&DS cancellations rise, backlog burn slows; FX and rate headwinds. FY27E adj EPS misses to ~$13; multiple de-rates to ~12× on leverage. | ~$156 (−25%) |
Synthos fair value = the base case, ~$227 (+10%), with the full $156–$270 span as the honest range. This anchor sits essentially on top of the Street's $222.4 consensus (we see modest upside, not a mispricing), while our bear is below the Street's $185 low (we take the leverage-plus-cyclicality tail seriously). This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). IQV is a decent compounder with little exponential character:
- Forward growth: revenue CAGR FY25→FY30E ~5.6% ($16.31B → $21.46B); adjusted-EPS CAGR FY26E→FY30E ~12.2% ($12.82 → $20.34), the gap driven by buybacks and modest margin lift, not by top-line acceleration.
- Acceleration (the 2nd derivative) is flat-to-negative: reported revenue growth was +5.9% (FY25) and consensus sees +6.0% (FY26E) → +5.6% (FY27E) → +5.4% (FY28E). Q1'26 organic growth did re-accelerate (mgmt: "more than anticipated," +6.0% constant-currency), which is the bull's toehold — but the multi-year trend is a steady mid-single-digit grinder, not an inflection.
- Room to run: the CRO + pharma-analytics TAM is large (tens of billions) but slow-growing and competitive; at $34.6B market cap IQV is already the category leader, so there is no small-cap "room" tailwind. A 3× from here would require either a durable growth re-acceleration or a major multiple re-rating — neither is the base case.
- Reinvestment runway: capital goes to tuck-in M&A (~$1.8B acquisitions in FY25) and buybacks (~$1.24B FY25) rather than a transformational organic reinvestment story; ROIC ~8.4% is respectable but not elite.
Exponential Potential: Low (3/10). Own IQV for steady ~10–12% adjusted-EPS compounding and a possible funding-recovery re-rating — not for a fast multibagger. This is squarely a satellite value/quality name, not a Degen-tier or a Core-compounder position.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $16.31B, +5.9% (FY24 $15.41B, +2.8% on FY23 $14.98B). Steady mid-single-digit growth; the FY20→FY25 CAGR (~7.5%) is flattered by the COVID-trial surge.
- Quarterly trajectory: Q1'25 $3.83B → Q2 $4.02B → Q3 $4.10B → Q4 $4.36B → Q1'26 $4.15B (+8.4% reported, +6.0% constant-currency YoY). A modest re-acceleration off a soft 2024/25 stretch.
- Margins: gross ~26% TTM (note: IQV reports high pass-through/reimbursed costs, so gross margin understates economics), EBITDA margin 21.2% TTM, operating ~14%, net 8.3% TTM. Adjusted EBITDA $3.46B FY25. Margins are stable, not expanding much.
- Earnings: GAAP net income $1.36B FY25 (roughly flat YoY); GAAP EPS $7.91 (diluted $7.84). On an adjusted basis management guides FY26 EPS to $12.65–$12.95 — the Street works off the adjusted number.
- Cash flow: operating CF $2.65B, capex −$0.60B, FCF ~$2.05B FY25 (FCF yield ~7.4% on market cap). Q1'26 FCF +15% YoY at ~100% of adjusted net income — a genuine quality tell.
- Balance sheet: total debt $16.2B, net debt $14.2B, net-debt/EBITDA ~4.0× (TTM basis; management cites a 3.62× net-leverage ratio on adjusted EBITDA). Interest coverage ~3.0×. Goodwill + intangibles are ~72% of assets (the IMS/Quintiles merger legacy). This leverage is the single biggest fundamental caveat — serviceable against $2B+ FCF, but it removes balance-sheet optionality and amplifies equity risk in a downturn.
6. Valuation — priced in or room?
Unlike most quality-franchise names, IQV is not obviously expensive. Trailing P/E is 25×, but the forward picture is reasonable: on management's/Street's adjusted EPS, the forward P/E is ~16× (FY26E) → ~15× (FY27E) → ~10× (FY30E), and EV/EBITDA is 13.8× against ~6% growth (a ~2.3× EV/EBITDA-to-growth, or ~2.4× forward PEG). That is a fair-to-slightly-cheap price for a category leader with 22% ROE and ~$2B FCF — the market is not paying up for IQV, largely because of the biotech-funding overhang and the leverage. Street targets (context): consensus $222.4, high $250, low $185 (1 Strong Buy · 35 Buy · 7 Hold · 1 Sell; FMP letter rating B+). Our $227 base-case FV is essentially in line with consensus — we see modest upside, not a large mispricing. Not a deep-value buy and not a stretched-multiple growth buy; a fairly-valued-quality buy whose upside depends on a funding recovery re-rating.
7. Technicals (from the tech block)
- Trend: up but extended. $207 sits above the 50-DMA ($176) and 200-DMA ($195), with the 50 now back above where it spent much of the drawdown — a recovery posture. MACD +6.1 (positive).
- Location: −15% off the 52-week high ($244) and +32% off the 52-week low ($157) — recovered most, but not all, of a rough stretch; the trailing-year max drawdown was −27%, a reminder this is a higher-beta name.
- Momentum: RSI(14) 73.6 — overbought (>70). This is a near-term caution flag: the stock has run hard into earnings and an entry here risks buying a local top. Prefer scaling in or waiting for a pullback toward the 50-DMA (~$176).
- Relative strength: IQV +27% 12-mo vs SPY +21% and QQQ +30% — ahead of the market, behind the Nasdaq; +20% 3-mo vs SPY +14%. Note the −9% 6-month figure: the recovery is recent and choppy, not a steady leadership uptrend.
- Read: technicals are constructive on trend but flash overbought on momentum. No reason to chase; a rising-50-DMA pullback would be a lower-risk add.
8. Moat & competitive position
IQVIA's moat is real but narrower than a branded-pharma moat: (1) proprietary health data at scale — the IMS Health heritage gives it a data asset that is expensive and slow to replicate, feeding high-margin analytics; (2) CRO scale and switching costs — a $34.2B contracted backlog and deep, multi-year sponsor relationships make it costly for pharma to move trials; (3) integrated data-plus-execution — the combination of real-world data, analytics, and trial execution under one roof is genuinely differentiated. The offsetting weakness: much of the R&DS book is cancellable on short notice and cyclically tied to biotech R&D budgets, so the moat protects share more than it protects near-term revenue.
Competitive frame: direct CRO peers are ICON plc and the former PPD (now Thermo Fisher's clinical business); on data/analytics it competes with Veeva, Definitive Healthcare, and others. The FMP "peer set" below is a healthcare-tools/services basket, not a like-for-like CRO comp — useful only as a valuation backdrop.
Peer set (FMP, market cap): Cardinal Health $56B, Humana $48B, Haleon $43B, Agilent $37B, Alcon $34B, ResMed $30B, GE HealthCare $30B, Illumina $29B, Mettler-Toledo $26B, Waters $25B. IQV ($34.6B) sits mid-pack on size; its ~16× forward earnings is toward the cheaper end of this quality-tools group.
9. Management, capital allocation & guidance
- Capital allocation: balanced but leverage-constrained — ~$1.8B of tuck-in acquisitions and ~$1.24B of buybacks in FY25 (share count down from ~192M in 2021 to ~171M), no dividend. Buybacks are the primary shareholder return; $1.22B of repurchase authorization remained at Q1'26. Debt reduction is a stated priority given the 3.6–4.0× leverage.
- Insider activity: the sampled window (Apr–May 2026) shows only routine director equity awards (deferred/common shares granted), no open-market discretionary buying or selling clusters — neutral signal.
- Management's own guidance (the earnings-call track — half-weighted, self-interested): in the May 5, 2026 Q1'26 release, management reaffirmed FY26 revenue of $17.15–17.35B and adjusted EBITDA of $3.975–4.025B, and raised FY26 adjusted diluted EPS guidance to $12.65–$12.95. They cited organic growth "accelerating more than anticipated," a Q1 book-to-bill of 1.04× (1.11× trailing-twelve-month), $34.2B R&DS backlog with ~$8.9B expected to convert in the next twelve months (+7.6% YoY), and FCF at 100% of adjusted net income. Guidance assumes ~150bps of M&A contribution and ~100bps FX tailwind. This is management's own book and is weighted at half — but the raised EPS guide and reaffirmed revenue/EBITDA are a real, dated data point supporting the base case. This is genuine forward guidance from an actual earnings release, not boilerplate.
10. Catalysts & what to watch
- Next earnings: 2026-07-28 (Q2'26; Street EPS $3.03, revenue ~$4.31B). The key lines: R&DS net new bookings and book-to-bill (funding-cycle read) and any change to the reaffirmed FY26 revenue/EBITDA guide.
- Biotech funding indicators: small/mid-cap biotech capital raises and cancellation rates — the leading indicator for R&DS bookings and the whole bull/bear split.
- Backlog burn: the ~$8.9B of backlog expected to convert in the next twelve months (+7.6% YoY) — watch conversion pace.
- Commercial/AI traction: whether "AI-enabled offerings gaining traction" shows up as durable Commercial Solutions margin/growth, not just commentary.
- Deleveraging: progress toward a lower net-leverage ratio — the key to a Downside-Risk-score upgrade.
Thesis tripwires (what would change the call): two consecutive quarters of book-to-bill below 1.0×; a cut to FY26 revenue/EBITDA guidance; net leverage rising back above ~4.2×; or FCF conversion falling well below ~90% of adjusted net income.
11. Key risks
- Biotech R&D-funding cyclicality (structural): the R&DS order book is cancellable and sensitive to pharma/biotech budgets; a funding drought hits bookings and revenue directly. This is the dominant risk.
- Leverage: ~4.0× net-debt/EBITDA (3.62× on adjusted) leaves limited balance-sheet cushion and amplifies equity downside; higher-for-longer rates raise the ~$729M annual interest bill.
- Slow organic growth / limited re-rating: at ~6% top-line growth, the equity return leans on buybacks and multiple stability; a de-rate is a real risk if growth disappoints.
- No expert coverage / low conviction: the Synthos KB has zero traceable claims on IQV — the call has no independent-panel support and should be sized conservatively.
- Overbought entry / FX: RSI 73.6 flags near-term stretch; ~52% of revenue is non-Americas, adding FX translation noise to reported growth.
12. Verdict, position sizing & monitoring
Buy — Tactical. IQVIA is a genuinely high-quality, hard-to-replicate franchise (dominant CRO + a proprietary health-data moat, 22% ROE, ~$2B FCF at ~100% conversion, re-accelerating organic growth per Q1'26) trading at a fair ~16× forward adjusted earnings — modest upside to our ~$227 base case, in line with the Street's $222 consensus. But it is held back from Core status by three honest facts: ~4× net leverage, a cyclical, cancellable order book tied to biotech funding, and — critically — no expert coverage in the Synthos KB, so conviction is Low.
- Sizing: satellite/tactical, ~1.5–3% of the flagship — a value-tilted quality name to own in size only on a pullback, not a bedrock anchor. RSI 73.6 argues for scaling in (a starter now, adds toward the ~$176 50-DMA) rather than a lump at an overbought level.
- Monitoring: re-underwrite on the §10 tripwires — especially book-to-bill and FY26 guidance — and re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $207.04.
- Single biggest risk: biotech/pharma R&D-funding cyclicality hitting R&DS bookings — the whole bull case depends on the funding environment staying stable-to-improving.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of IQV in the Synthos knowledge base, so no
claim_ids are cited. The verdict is explicitly fundamentals- and quant-driven; conviction is Low. Fabricated conviction is structurally impossible (we cite only real claim-IDs, and here there are none). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: FY26 guidance (reaffirmed revenue/EBITDA, raised adj-EPS to $12.65–$12.95) is management's own book, half-weighted by design; sourced from the SEC 8-K/EX-99.1 Q1'26 earnings release dated 2026-05-05.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").